Skip to main content

Current and emerging treatment options in triple-negative breast cancer

Abstract

Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triple-negative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the biology of TNBC has led to evaluation of DNA-damaging chemotherapy drugs and targeted agents, including poly(ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, etc., in the treatment of TNBC. This review focuses on outlining the current and emerging treatment options in patients with triple-negative breast cancer.

This is a preview of subscription content, access via your institution.

References

  1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  2. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374

    Article  CAS  PubMed  Google Scholar 

  3. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018

    Article  CAS  PubMed  Google Scholar 

  4. Conforti R, Bidard FC, Michiels S (2007) Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers. Breast Cancer Res Treat 106(suppl 135), abstract 3030

    Google Scholar 

  5. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244

    Article  PubMed  Google Scholar 

  6. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307

    Article  PubMed  CAS  Google Scholar 

  7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502

    Article  CAS  PubMed  Google Scholar 

  8. Burnell MJ, O’Connor EM, Chapman JW, Levine MN, Pritchard KI, O’Brian PS, et al (2008) Triple-negative receptor status and prognosis in the NCIC CTG MA.21 adjuvant breast cancer trial. J Clin Oncol 26(suppl 15), abstract 550

    Google Scholar 

  9. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434

    Article  PubMed  Google Scholar 

  10. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R (2008) Triple-negative breast cancer. Curr Opin Oncol 20:614–620

    Article  PubMed  Google Scholar 

  11. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533–1539

    Article  CAS  PubMed  Google Scholar 

  12. Sasaki Y, Tsuda H (2009) Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 16:254–259

    Article  PubMed  Google Scholar 

  13. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271

    Article  CAS  PubMed  Google Scholar 

  14. Aksoy S, Dizdar O, Harputluoglu H, Altundag K (2007) Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol 18:1904–1906

    Article  CAS  PubMed  Google Scholar 

  15. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581

    Article  PubMed  Google Scholar 

  16. Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S et al (2009) Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 113:181–187

    Article  PubMed  CAS  Google Scholar 

  17. Couch FJ (2004) Genetic epidemiology of BRCA1. Cancer Biol Ther 3:509–514

    CAS  PubMed  Google Scholar 

  18. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86

    Article  CAS  PubMed  Google Scholar 

  19. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288

    Article  PubMed  Google Scholar 

  20. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485

    CAS  PubMed  Google Scholar 

  21. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318

    Article  CAS  PubMed  Google Scholar 

  22. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  CAS  PubMed  Google Scholar 

  23. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853

    Article  CAS  PubMed  Google Scholar 

  24. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120–1123

    CAS  PubMed  Google Scholar 

  25. Sylvain V, Lafarge S, Bignon YJ (2002) Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20:845–853

    CAS  PubMed  Google Scholar 

  26. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281

    Article  PubMed  Google Scholar 

  27. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334

    Article  CAS  PubMed  Google Scholar 

  28. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635–692

    Article  CAS  PubMed  Google Scholar 

  29. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14–20

    CAS  PubMed  Article  Google Scholar 

  30. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S et al (2000) Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839–847

    CAS  PubMed  Google Scholar 

  31. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV et al (2005) retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483–7490

    Article  CAS  PubMed  Google Scholar 

  32. Bofin AM, Ytterhus B, Hagmar BM (2003) TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14:314–319

    Article  CAS  PubMed  Google Scholar 

  33. Delaloge S, Pautier P, Kloos I (2002) BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. In: Paper presented at 27th congress of the European society for medical oncology, 18–22 October 2002, Nice, France (abstract #120)

  34. Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI et al (2009) Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27(suppl 15), abstract 519

    Google Scholar 

  35. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2006) BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001–1007

    CAS  PubMed  Google Scholar 

  36. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685

    Article  CAS  PubMed  Google Scholar 

  37. Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Duenas-Garcia R, Jaen-Morago A, Ortega-Granados AL et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646–653

    Article  CAS  PubMed  Google Scholar 

  38. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506

    Article  CAS  PubMed  Google Scholar 

  39. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456–1466

    Article  CAS  PubMed  Google Scholar 

  40. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228–233

    Article  CAS  PubMed  Google Scholar 

  41. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E et al (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23:1951–1961

    Article  CAS  PubMed  Google Scholar 

  42. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174

    Article  CAS  PubMed  Google Scholar 

  43. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  CAS  PubMed  Google Scholar 

  44. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D et al (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99:327–334

    Article  CAS  PubMed  Google Scholar 

  45. Altundag K, Bulut N, Dizdar O, Harputluoglu H (2006) Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007. Breast Cancer Res Treat 100:329–330

    Article  PubMed  Google Scholar 

  46. Veerapaneni A, Boisvert M, Choi A, Aggarwal A (2008) Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer. J Clin Oncol 26 (suppl, abstr 11535)

  47. Yardley DA, Inhorn RC, Daniel D, Daniel B, Naot Y, Zubkus J et al (2008) Phase II study of neoadjuvant gemcitabine, epirubicin, and albumin-bound nab paclitaxel (GEA) in locally advanced breast cancer with SPARC tumor assessments. J Clin Oncol 26(suppl 15), abstract 603

    Google Scholar 

  48. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027

    Article  CAS  PubMed  Google Scholar 

  49. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847–1852

    Article  CAS  PubMed  Google Scholar 

  50. Yi S, Uhm J, Cho E, Lee S, Park M, Jun H et al (2008) Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. J Clin Oncol 26(suppl 15), abstract 1008

    Google Scholar 

  51. Garber JE, Richardson A, Harris LN, Miron A, Silver D, Golshan M et al (2006) Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). In: 29th Annual San Antonio breast cancer symposium. San Antonio, Texas (abstract 3074)

  52. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C et al (2008) Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115:359–363

    Article  PubMed  CAS  Google Scholar 

  53. Chang HR, Slamon D, Gornbein JA, Chung D (2008) Preferential pathologic complete response (pCR) by triple-negative (−) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C). J Clin Oncol 26(suppl 15), abstract 604

    Google Scholar 

  54. Leone JP, Guardiola V, Venkatraman A, Pegram MD, Welsh C, Silva O et al (2009) Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients. J Clin Oncol 27(suppl 15), abstract 625

    Google Scholar 

  55. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS et al (2008) A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 98:1327–1335

    Article  CAS  PubMed  Google Scholar 

  56. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F et al (2008) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 62:667–672

    Article  CAS  PubMed  Google Scholar 

  57. Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D’Aiuto M et al (2009) Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 20:1185–1192

    Article  CAS  PubMed  Google Scholar 

  58. Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B et al (2009) A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer 9:166–172

    Article  CAS  PubMed  Google Scholar 

  59. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA et al (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group study. J Clin Oncol 27:4693–4700

    Article  CAS  PubMed  Google Scholar 

  60. Rugo HS, Roche H, Thomas E, Blackwell K, Chung HC, Lerzo G et al (2008) Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. In: 31st Annual San Antonio breast cancer symposium. San Antonio, Texas (abstract 3057)

  61. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A et al (2008) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19:861–870

    Article  CAS  PubMed  Google Scholar 

  62. Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H et al (2007) Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13:488–497

    Article  CAS  PubMed  Google Scholar 

  63. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE et al (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17:588–596

    Article  CAS  PubMed  Google Scholar 

  64. Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P (2008) et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26:37–43

    Article  CAS  PubMed  Google Scholar 

  65. De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F et al (2007) High-dose chemotherapy for triple negative breast cancer. Ann Oncol 18:202–203

    Article  PubMed  Google Scholar 

  66. Farquhar CM, Marjoribanks J, Lethaby A, Basser R (2007) High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33:325–337

    Article  CAS  PubMed  Google Scholar 

  67. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525–1533

    CAS  PubMed  Google Scholar 

  68. Carey LA, Rugo HS, Marcom PK, Irvin W, Ferrano M, Burrows E et al (2008) TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 26(suppl 15), abstract 1009

    Google Scholar 

  69. O’Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes FA et al (2007) Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106(suppl 32), abstract 308

    Google Scholar 

  70. Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM et al (2008) N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol 26 (suppl, abstr 1081)

  71. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP (2008) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 115:115–121

    Article  PubMed  CAS  Google Scholar 

  72. Corkery B, Crown J, Clynes M, O’Donovan N (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862–867

    Article  CAS  PubMed  Google Scholar 

  73. Rougier P, Stroiakovski D, Köhne C, Chang Chien C, Lim R, Pintér T et al (2009) Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study. In: 2009 Gastrointestinal cancers symposium (abstract #443)

  74. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407–5414

    CAS  PubMed  Google Scholar 

  75. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639–1646

    Article  CAS  PubMed  Google Scholar 

  76. Sirohi B, Smith K (2008) Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 8:1559–1568

    Article  CAS  PubMed  Google Scholar 

  77. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  78. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K et al (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 35:1048–1054

    CAS  PubMed  Google Scholar 

  79. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816

    Article  CAS  PubMed  Google Scholar 

  80. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819

    Article  CAS  PubMed  Google Scholar 

  81. Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176–1178

    CAS  PubMed  Google Scholar 

  82. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134

    Article  CAS  PubMed  Google Scholar 

  83. O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G et al (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(suppl 18), abstract 3

    Google Scholar 

  84. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN et al (2009) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 27 (suppl, abstr CRA501)

Download references

Conflict of interest statement

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kadri Altundag.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dizdar, O., Altundag, K. Current and emerging treatment options in triple-negative breast cancer. Oncol Rev 4, 5–13 (2010). https://doi.org/10.1007/s12156-009-0031-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-009-0031-6

Keywords

  • Breast cancer
  • Triple-negative
  • Basal-like
  • Treatment